CoChat

A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

Open access
Furihata, Kenichi, Mimura, Hanaka, Urva, Shweta, Oura, Tomonori, Ohwaki, Kenji, Imaoka, Takeshi · 2022 · Diabetes, Obesity and Metabolism
Cited by 59

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim: To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). Methods: This phase 1, double‐blind, placebo‐controlled, parallel‐dose, multiple‐ascending dose study randomized participants to once‐weekly subcutaneous tirzepatide or placebo. The tirzepatide treatment groups were: 5 mg (5 mg, weeks 1‐8), 10 mg (2.5 mg, weeks 1‐2; 5 mg, weeks 3‐4; 10 mg, weeks 5‐8), and 15 mg (5 mg, weeks 1‐2; 10 mg, weeks 3‐6; 15 mg, weeks 7‐8). The primary outcome was tirzepatide safety and tolerability. Results: Forty‐eight participants were randomized. The most frequently reported treatment‐emergent adverse events (AEs) were decreased appetite and gastrointestinal AEs, which were generally dose‐dependent and mild in severity. The plasma tirzepatide concentration half‐life was approximately 5 days. After 8 weeks of treatment, fasting plasma glucose decreased from baseline with tirzepatide versus placebo; the least squares (LS) mean decrease compared with placebo (95% confidence interval [CI]) was 52.7 (35.9‐69.6), 69.1 (52.3‐85.9), and 68.9 (53.2‐84.6) mg/dL in the 5‐, 10‐, and 15‐mg treatment groups, respectively ( P < .0001 for all treatment groups). Tirzepatide also resulted in LS mean decreases from baseline versus placebo at 8 weeks in HbA1c up to 1.6% (95% CI 1.2%‐1.9%; P < .0001 for all treatment groups) and body weight up to 6.6 kg (95% CI 5.3‐7.9; P < .0001 for all treatment groups). Conclusions: All tirzepatide doses were well tolerated. The safety, tolerability, PK, and PD profiles of tirzepatide support further evaluation of once‐weekly dosing in Japanese people with T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14572

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 59

Metadata

Authors
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2021-11-18
Volume
24
Issue
2
Pages
239-246
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3206180121
Cited by
59
References
12
FWCI
6.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.14572
The paper
Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022). A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14572

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.